- Home
- CERS vs RLMD Comparison
CERS vs RLMD Comparison
Compare CERS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- RLMD
- Stock Information
- Founded
- CERS 1991
- RLMD 2004
- Country
- CERS United States
- RLMD United States
- Employees
- CERS N/A
- RLMD N/A
- Industry
- CERS EDP Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- CERS Technology
- RLMD Health Care
- Exchange
- CERS Nasdaq
- RLMD Nasdaq
- Market Cap
- CERS 276.0M
- RLMD 289.7M
- IPO Year
- CERS 1997
- RLMD N/A
- Fundamental
- Price
- CERS $1.69
- RLMD $4.21
- Analyst Decision
- CERS Buy
- RLMD Buy
- Analyst Count
- CERS 1
- RLMD 2
- Target Price
- CERS $4.00
- RLMD $5.50
- AVG Volume (30 Days)
- CERS 1.3M
- RLMD 2.1M
- Earning Date
- CERS 11-06-2025
- RLMD 11-13-2025
- Dividend Yield
- CERS N/A
- RLMD N/A
- EPS Growth
- CERS N/A
- RLMD N/A
- EPS
- CERS N/A
- RLMD N/A
- Revenue
- CERS $199,191,000.00
- RLMD N/A
- Revenue This Year
- CERS $19.07
- RLMD N/A
- Revenue Next Year
- CERS $12.03
- RLMD N/A
- P/E Ratio
- CERS N/A
- RLMD N/A
- Revenue Growth
- CERS 13.03
- RLMD N/A
- 52 Week Low
- CERS $1.12
- RLMD $0.24
- 52 Week High
- CERS $2.24
- RLMD $5.12
- Technical
- Relative Strength Index (RSI)
- CERS 59.26
- RLMD 75.52
- Support Level
- CERS $1.47
- RLMD $3.81
- Resistance Level
- CERS $1.78
- RLMD $5.12
- Average True Range (ATR)
- CERS 0.13
- RLMD 0.56
- MACD
- CERS 0.01
- RLMD 0.08
- Stochastic Oscillator
- CERS 78.75
- RLMD 66.67
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.